Overview

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Eltrombopag is a compound that may help stimulate the production of platelets. This drug has been used in treatment of low platelet counts caused by a disorder called idiopathic thrombocytopenic purpura and information from those other research studies suggests that Eltrombopag may help to maintain platelet counts in patients with relapsed multiple myeloma in this research study. In this research study,the investigators are trying to determine if Eltrombopag is effective in maintaining platelet counts in patients who are being treated for relapsed multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute